Combination therapy for the analogous drug targets of MEK1/2, CDK4/6, and PLK1 have been reported but paint an incomplete and inconsistent picture, which may be due to the lack of consistent experimental and analytical systems for evaluating synergy, as well as the large variation between different tumor and cancer cell line types. This evidence concerns the gene PLK1 and cancer.